Vaxcyte CTO Harpreet Dhaliwal Exercises Options, Sells 17k Shares

What Happened
Harpreet S. Dhaliwal, Chief Technical Operations Officer of Vaxcyte, exercised 17,000 fully vested stock options at $24.79 per share (total cost $421,430) on Aug 5, 2026 and sold 17,000 shares in the open market the same day for gross proceeds of approximately $935,068 (weighted-average sale price reported as $55.00). The filing also reports the conversion/disposition of the derivative (the option) related to the exercise.

Key Details

• Transaction date: 2026-08-05.
• Option exercise: 17,000 shares acquired at $24.79 each — total exercise cost $421,430 (Footnote F4: option fully vested).
• Open-market sale: 17,000 shares sold for $55.00 (weighted-average); gross proceeds reported $935,068. Footnote F3 notes sale prices ranged $55.00–$55.255 and the weighted-average is reported; detailed price-by-price breakdown available upon request.
• Reported pursuant to a Rule 10b5-1 trading plan adopted April 6, 2026 (Footnote F2).
• Filing does not specify shares owned after the transaction in the provided summary.
• Footnote F1 notes 780 shares were acquired under the company ESPP on May 15, 2026 (included in beneficial ownership reporting).
• No late filing flag indicated; transaction and report date are the same (timely).

Context

• This was an exercise of vested options followed by a same-day sale of the resulting shares (effectively realizing the gain between the $24.79 exercise price and the ~$55 sale price). Such exercise-and-sell transactions are common for insiders seeking liquidity or to cover option exercise costs and do not, by themselves, indicate the insider’s view of the company’s future performance.
• The sale was executed under a pre-established 10b5-1 plan, which regularly governs timing of insider trades to avoid allegations of trading on material nonpublic information.